The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes
Abstract
Anthracyclines are powerful anticancer agents and among the most important tools in the chemotherapy armamentarium of medical oncologists. They are approved for use in the treatment of a broad variety of solid and hematologic neoplasms. However, the usefulness of these agents, particularly doxorubicin, the most widely used anthracycline, is limited by considerable toxicity, especially damage to the cardiac muscle, which is cumulative and mostly irreversible, restricting extended use of this drug. In the last 30 years, extensive research with a variety of drug-delivery systems has attempted to overcome this limitation, with clinical success mostly confined to liposome formulations. Liposomal doxorubicin, and particularly pegylated liposomal doxorubicin, has shown significant pharmacologic advantages and an added clinical value over doxorubicin. Here, we review the mechanisms of action and toxicity of doxorubicin, and ways to reduce toxicity, with a focus on liposome-based drug-delivery systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Liposome application: problems and prospects.
Barenholz, Y. (2001) · Current Opinion in Colloid & Interface Science · doi:10.1016/s1359-0294(00)00090-x · Cited by 659
Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., & Muggia, F. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg374 · Cited by 479
Kwon, G., Suwa, S., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (1994) · Journal of Controlled Release · doi:10.1016/0168-3659(94)90118-x · Cited by 409
Yokoyama, M. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00115-6 · Cited by 308
Oxidant-Induced Iron Signaling in Doxorubicin-Mediated Apoptosis
Kotamraju, S., Kalivendi, S. V., Konorev, E., Chitambar, C. R., Joseph, J., & Kalyanaraman, B. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)78026-x · Cited by 66
Cited by
Fertility Preservation in Women
Donnez, J., & Dolmans, M.-M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1614676 · Cited by 853
Liposomal Drug Delivery Systems and Anticancer Drugs
Olusanya, T., Haj Ahmad, R., Ibegbu, D., Smith, J., & Elkordy, A. (2018) · Molecules · doi:10.3390/molecules23040907 · Cited by 603
Wenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.115725 · Cited by 334
Yang, W., Wang, L., Mettenbrink, E. M., DeAngelis, P. L., & Wilhelm, S. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032320-110338 · Cited by 327
Ferritin nanocages: A biological platform for drug delivery, imaging and theranostics in cancer
Truffi, M., Fiandra, L., Sorrentino, L., Monieri, M., Corsi, F., & Mazzucchelli, S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.002 · Cited by 277
Metadata
- Authors
- Tahover, E., Patil, Y. P., & Gabizon, A. A.
- Venue
- Anti-Cancer Drugs
- Published
- 2015-03
- Volume
- 26
- Issue
- 3
- Pages
- 241-258
- ISSN
- 0959-4973 (ISSN-L)
- OpenAlex
- W2331664759
- Cited by
- 160
- References
- 9
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes. https://app.cochat.ai/papers/10.1097/cad.0000000000000182
- The paper
- Tahover, E., Patil, Y. P., & Gabizon, A. A. (2015). Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes. Anti-Cancer Drugs. https://doi.org/10.1097/cad.0000000000000182
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.